Semaglutide generics’ future depends on API capacity: Goldman Sachs
Goldman Sachs reports the future of semaglutide genericisation and GLP-1 pricing hinges on peptide API manufacturing capacity, not demand. China is poised to be a key generic supplier, with manufacturing scalability being a major uncertainty. The speed of semaglutide genericisation and GLP-1 pricing after 2031/32 will likely depend less on demand and more on peptide … Read more